Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-06
2008-05-06
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S027230
Reexamination Certificate
active
07368438
ABSTRACT:
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4794174 (1988-12-01), Secrist, III
patent: 5049550 (1991-09-01), Zamecnik
patent: 5292725 (1994-03-01), Prendergast
patent: 5409937 (1995-04-01), Whittaker et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 6037343 (2000-03-01), Ali
patent: 6040317 (2000-03-01), Duggan et al.
patent: 6369064 (2002-04-01), Brown et al.
patent: 6767910 (2004-07-01), Teobald
patent: 2004/0138229 (2004-07-01), Bryant et al.
patent: 2005/0267134 (2005-12-01), Plourde et al.
patent: 0 066 918 (1982-12-01), None
patent: 1 348 466 (2003-10-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 99/05142 (1999-02-01), None
patent: WO 99/05143 (1999-02-01), None
patent: WO 99/05144 (1999-02-01), None
patent: WO99/06053 (1999-02-01), None
patent: WO 99/41254 (1999-08-01), None
patent: WO 00/04021 (2000-01-01), None
patent: WO00/33080 (2000-06-01), None
patent: WO 01/36438 (2001-05-01), None
patent: WO 01/40243 (2001-06-01), None
patent: WO 01/40246 (2001-06-01), None
patent: WO 01/94368 (2001-12-01), None
patent: WO 02/16381 (2002-02-01), None
patent: WO 02/096428 (2002-12-01), None
Lambertucci, et al. “2-Phenylhydroxypropynyladenosine Derivatives as High Potent Agonists at A2B Adenosine Receptor Subtype,” Nucleosides, Nucleotides & Nucleic Acids, 2003, vol. 22, Nos. 5-8, pp. 809-812.
Abstracts of Papers, 225THACS National Meeting, New Orleans, LA; Mar. 2003; MEDI-016.
André, et al., “P2Y12regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries,”J. Clin. Invest., 112: 398-406 (2003).
Antiplatelet Trialists' Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy Prevention of death, myocardial antiplatelet therapy in various categories of patients,”Br. Med. J. 308: 81-106 (1994).
Antiplatelet Trialists' Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy—II: Maintenance of vascular antiplatelet therapy,”Br. Med. J. 308: 159-168 (1994).
Baraldi, et al., “NovelN6-(Substituted-phenylcarbamoyl)adenosine-5′-uronamides as Potent Agonists for A3Adenosine Receptors,”Journal of Medicinal Chemistry39(3): 802-806 (1996.
Bennett, et al., “Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel,”N. Engl. J. Med. 342: 1773-1777 (2000).
Bennett, et al., “Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine,”Ann. Intern. Med. 128: 541-544 (1998.
Bernat, et al., “Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas. 70: 812-826 (1993).
Brown, et al., “Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2′ Residues,”J. Med. Chem. 37(5): 674-688 (1994).
Bush, et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries,”Circulation69: 1161-1170 (1984).
Camaioni, et al., “Adenosine Receptor Agonists: Synthesis and Biological Evaluation of the Diastereoisomers of 2-(3-Hydroxy-3-phenyl-1-propyn-1-yl)NECA,”Bioorganic&Medicinal Chemistry5(12): 2267-2275 (1997).
Cristalli, et al., “2-Aralkynyl and 2-Heteroalkynyl Derivativse of Adenosine-5′-N-ethyluronamide as Selective A2aAdenosine Receptor Agonists,”Journal of Medicinal Chemistry38(9): 1462-1472 (1995).
Dangelmaier, et al., “Potentiation of Thromboxane A2-induced Platelet Secretion by Gi Signaling through the Phosphoinositide-3 Kinase Pathway,”Thromb. Haemostas. 85: 341-348 (2001).
The EPIC investigators; Califf, R.M. coordinating author; “Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty,”New Engl. J. Med. 330: 956-961 (1994).
Folts, et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin,”Circulation54: 365-370 (1976).
Frederick et al., “The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis,”Circulation93: 129-134 (1996).
Gachet, C., “ADP Receptors of Platelets and their Inhibition,”Thromb. Haemostas. 86: 222-232 (2001).
Garcia-Echeverria, C., “A base labile handle for solid phase organic chemistry,”Tetrahedron Lett., 38: 8933-8937 (1997).
Gelger, et al., “Specific Impairment of Human Platelet P2YACADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel,”Arteriocler. Thromb. Vasc. Biol. 19: 2007-2011 (1999).
The GUSTO IIa investigators; “Randomized Trial of Intravenous Heparin Versus Recombinant Hirudin for Acute Coronary Syndromes,”Circulation90: 1631-1637 (1994).
Hass, et al., “A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients,”N. Engl. J. Med. 321: 501-507 (1989).
Hechler, et al., “A Role of the Fast ATP-gated P2X1Cation Channel in Thrombosis of Small Arteries In Vivo,”J. Exp. Med. 198: 661-667 (2003).
Herbert, et al., “Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits,”Arterioscl. Thromb. 13: 1171-1179 (1993).
Hourani, et al., “Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5′-diphosphate,”Br. J. Pharmacology105: 453-457 (1992).
The IMPACT-II Investigators; “Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II,”Lancet349: 1422-1428 (1997).
Ingall, et al., “Antagonists of the Platelet P2TReceptor: A Novel Approach to Antithrombotic Therapy,”J. Med. Chem. 42: 213-220 (1999).
Jacobson, et al., “Structure-Activity Relationships of 9-Alkyladenine and Ribose-Modified Adenosine Derivatives at Rat A3Adenosine Receptors,”Journal of Medicinal Chemistry38(10): 1720-12735 (1995).
Jagroop, et al., “Both the ADP receptors P2Y1and P2Y12, play a roll in controlling shape change in human platelets,”Platelets14: 15-20 (2003).
Lee, et al., “N-Alkoxysulfamide,N-Hydroxysulfamide, and Sulfamate Analogues of Methionyl and Isoleucyl Adenylates as Inhibitors of Methionyl-tRNA and Isoleucyl-tRNA Synthetases,” Bioorganic &Medicinal Chemistry Letters13(6): 1087-1092 (2003).
Lekstrom and Bell, “Aspirin in the Prevention of Thrombosis,”Medicine70: 161-177 (1991).
Lyga and Secrist III, “Synthesis of Chain-Extended and C-6′ Functionalized Precursors of the Nucleoside Antibiotic Sinefungin,”Journal of Organic Chemistry48(12): 1982-1988 (1983).
Maffrand, et al., “ADP Plays a Key Role in Thrombogenesis in Rats,”Thromb. Haemostas. 59: 225-230 (1988).
McKee, et al., “Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance,”Thromb. Haemostas. 88: 711-715 (2002).
Mickelson, et al., “Antiplatelet Antibody [7E3 F(ab′)2] Prevents Rethrombosis
Abreo Melwyn A.
Alfaro-Lopez Lorenzo J.
Boyer José L.
Feng Yangbo
Harvey Daniel F.
Bland Layla
Howrey LLP
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Kung Viola T.
LandOfFree
Non-nucleotide compositions and method for inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-nucleotide compositions and method for inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-nucleotide compositions and method for inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2794073